Background
The p53 tumor suppressor can drive stressed cells into senescence or apoptosis. One of the key negative regulators that keeps p53 in check in unstressed cells and limits p53's response under stress is the E3 ubiquitin ligase MDM2 [
1]. A disequilibrium in the levels of MDM2 and p53 is associated with distinct phenotypes. For example, reduction of MDM2 expression in mice reduces adenoma formation [
2] whereas MDM2 deficiency causing overshooting p53 activity was reported to be lethal [
3,
4]. On the other hand, overproduction of MDM2 is accompanied by a reduction of p53 activity and is a hallmark of some tumor types in humans [
5‐
7]. Thus, inherited differences in the efficacy of the MDM2-mediated limitation of p53-response in stressed cells could be important determinants of efficient tumor suppression [
8].
Intracellular MDM2 expression is controlled at the levels of protein stability, gene transcription, and transcript translation [
1]. Upon stress or hormonal signalling, various transcription factors, among them p53 and the estrogen receptor ER-α [
9] bind to response elements of the
MDM2 gene promoter in the first intron. As a result, MDM2 levels rise and p53 activity is limited. Work by Bond and colleagues [
10‐
12] has recently indicated that a single nucleotide polymorphism at intron 1 position 309 (rs2279744) generates a novel binding site for the ubiquitous transcriptional activator SP1 and causes higher MDM2 levels and consequently, attenuated p53 response in stressed or estrogen-exposed cells.
The
p53 allele with a "C" instead of "G" at position 12139 (SNP72 C; rs1042522), coding for proline instead of arginine at amino acid position 72, occurs at a frequency of approximately 23% among Caucasians and is considered to be associated with at least some types of cancers [
13]. Observations by Hong and colleagues suggest that homozygosity for both SNP309 G and SNP72 C can be additive [
14]. The present study analyzes both polymorphisms in 311 patients with B-NHL and 512 healthy central Europeans of Caucasian ethnicity.
Discussion
The levels of the p53 tumor suppressor are primarily controlled by the E3 ubiquitin ligase MDM2 [
1].
MDM2 promoter polymorphism SNP309 G gives rise to higher levels of MDM2 in response to stress or estrogen, and consequently, inhibits p53 more efficiently than SNP309 T [
8,
10]. Several studies have implicated estrogen signalling manipulation in cancer incidence and progression (reviewed in [
23]), and in gender-specific differences in DLBCL incidence (for example, [
24]). In accord with these findings, Bond and colleagues have recently reported that women homozygous for SNP309 G were diagnosed with DLBCL on average 13 years earlier than women homozygous for the T allele (G/G women: 55 years; T/T women, 68 years), whereas men did not show such a correlation. They also documented that the G/G genotype is significantly more frequent among women diagnosed before menopause (10/21 G/G-individuals were diagnosed by age 51 vs. 0/21 T/T-individuals; 11/58 G/G women were diagnosed by age >51 vs. 13/58 T/T women), and suggested that estrogen may co-operate with the G allele to accelerate lymphoma formation [
11]. These findings could not be confirmed by our study; we observed only 3/20 G/G women diagnosed by age 51. In this context it should be noted that Bond et al. observed 24% G/G homozygotes among 976 healthy Caucasians of Ashkenazi Jewish descent, whereas we observed 14% in our healthy cohort of 512 central European Caucasians. Thus and in accord with these authors, Ashkenazi Jewish Caucasians have a significantly higher SNP309 G/G genotype frequency than Non-Ashkenazi Caucasians from central Europe (p < 0.001; Fisher's exact test).
MDM2 SNP309 T/G has originally been reported to be associated with an increased risk for tumor formation in patients with an inherited mutated p53 allele (Li-Fraumeni syndrome) and in patients with sporadic soft tissue sarcoma [
10]. It should be kept in mind though that MDM2 is a pleiotropic E3 ubiquitin ligase with many cellular targets besides p53, one of the latest on the list being topoisomerase II [
25]. SNP309 might therefore affect several cancer-relevant pathways. Homozygosity for SNP309 G has been linked to a significantly earlier onset of several hereditary and sporadic cancers, including breast carcinomas and osteosarcomas, but also to DLBCL, adult soft tissue sarcoma, invasive ductal breast cancer, and colorectal cancer specifically in women. The polymorphism has furthermore been associated with uterine leiomyosarcoma, squamous cell carcinoma of the head and neck, the outcome of breast cancer, non-small cell lung cancer, hepatocellular carcinoma in patients with chronic hepatitis C, gastric carcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, ovarial carcinoma, sporadic endometrial cancer, invasive bladder cancer, and renal cell carcinoma (for a recent review, see [
8]). However, other studies fail to show an association. For instance, age of onset of colorectal cancer in Lynch syndrome, lung cancer risk in a Chinese population, lung cancer risk, incidence of breast cancer in mutant BRCA1 carriers, incidence of breast and ovarian cancer, breast cancer risk in a Chinese population, breast cancer risk, age at diagnosis of HNPCC patients, basal cell carcinoma risk, risk and prognosis of glioblastoma (reviewed in [
8]), and finally NHL and DLBCL in Non-Ashkenazi European Caucasians (this study), were not associated with SNP309. This together with the discrepancy between our findings and that of Bond and colleagues on DLBCL [
11], points to the importance of other genetic modifiers in the p53 pathway.
Since its first description 20 years ago, hundreds of studies on the
p53 gene SNP72 polymorphism and cancer susceptibility have been completed. Positive correlations were reported, for instance, for hepatocellular carcinoma [
26], non-polyposis hereditary colorectal cancer [
27,
28], nasopharyngeal carcinoma [
29], and melanoma [
30]. Recent meta-analyses found positive correlations of the C/C genotype with gastric cancer in Asians [
31], esophageal cancer [
32], and overall cancer mortality [
33]. By contrast, other meta-analyses failed to find a correlation with lung cancer [
34] and breast cancer [
20]. No correlation was also found for acute myelogenous leukaemia [
35] and for multiple myeloma, except when studied in combination with other polymorphisms [
36]. Likewise, our study on patients with NHL and DLBCL failed to establish a correlation with SNP72 G/C. Neither
MDM2 gene SNP309 T/G nor
p53 gene SNP72 G/C influences diffuse-large B-cell lymphoma in central European Caucasians.
Conclusion
We found no evidence that MDM2 gene SNP309 or p53 gene SNP72 is associated with an increased risk for, or accelerated formation of, diffuse-large B-cell lymphoma in men or women of central European Caucasian ethnicity. Furthermore, neither SNP309 nor SNP72 was correlated with age of onset, diagnosis, or survival of patients. These polymorphisms may thus act as genetic modifiers in dependence of a population genetic background.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JB, FP, AW, MM and LK carried out the probe sampling and genetic analyses, MK performed the statistical analysis and helped with the manuscript, LT and MP collected and characterized the patients and participated in the design of the study and manuscript preparation, OL and AM designed and optimized the genotyping, KR conceived of the study, supervised the laboratory work, and prepared the manuscript. All authors read and approved the final manuscript.